TRLS Stock Overview
Provides digital chronic condition management solutions for employers and health plans. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Trellus Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0067 |
| 52 Week High | UK£0.074 |
| 52 Week Low | UK£0.006 |
| Beta | 0.15 |
| 11 Month Change | -5.59% |
| 3 Month Change | -46.00% |
| 1 Year Change | -85.79% |
| 33 Year Change | -98.82% |
| 5 Year Change | n/a |
| Change since IPO | -98.96% |
Recent News & Updates
Shareholder Returns
| TRLS | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -0.3% |
| 1Y | -85.8% | -24.2% | 6.1% |
Return vs Industry: TRLS underperformed the UK Healthcare industry which returned -24.2% over the past year.
Return vs Market: TRLS underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| TRLS volatility | |
|---|---|
| TRLS Average Weekly Movement | 14.3% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: TRLS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: TRLS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 31 | Marla Dubinsky | www.trellushealth.com |
Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers TrellusElevate, a proprietary HIPAA-compliant technology platform to coordinate and deliver personalized care remotely through telemedicine. Its platform provides patients with access to a care team, educational content resources, and remote monitoring capabilities for the treatment of inflammatory bowel diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis.
Trellus Health plc Fundamentals Summary
| TRLS fundamental statistics | |
|---|---|
| Market cap | UK£1.09m |
| Earnings (TTM) | -UK£5.27m |
| Revenue (TTM) | UK£43.53k |
25.0x
P/S Ratio-0.2x
P/E RatioIs TRLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRLS income statement (TTM) | |
|---|---|
| Revenue | US$55.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$55.00k |
| Other Expenses | US$6.72m |
| Earnings | -US$6.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 100.00% |
| Net Profit Margin | -12,114.55% |
| Debt/Equity Ratio | 0% |
How did TRLS perform over the long term?
See historical performance and comparison